Literature DB >> 1503894

Implications of an overview of chemotherapy in advanced ovarian carcinoma.

C J Williams.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1503894      PMCID： PMC1977818          DOI： 10.1038/bjc.1992.248

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  6 in total

1.  Best documented practice.

Authors:  J M Whitehouse
Journal:  BMJ       Date:  1989-06-10

2.  Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation).

Authors:  C J Cohen; J D Goldberg; J F Holland; H W Bruckner; G Deppe; S B Gusberg; R C Wallach; B Kabakow; J Rodin
Journal:  Am J Obstet Gynecol       Date:  1983-04-15       Impact factor: 8.661

3.  Adriamycin therapy for advanced ovarian carcinoma recurrent after chemotherapy.

Authors:  S M Hubbard; P Barkes; R C Young
Journal:  Cancer Treat Rep       Date:  1978-09

4.  A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma.

Authors:  E Wiltshaw; B Evans; G Rustin; E Gilbey; J Baker; G Barker
Journal:  J Clin Oncol       Date:  1986-05       Impact factor: 44.544

5.  Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.

Authors:  G A Omura; B N Bundy; J S Berek; S Curry; G Delgado; R Mortel
Journal:  J Clin Oncol       Date:  1989-04       Impact factor: 44.544

6.  Cisplatin (P) versus cyclophosphamide, adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: a prospective randomized trial.

Authors:  M Tomirotti; S Perrone; P Giè; R Canaletti; A Carpi; R Biasoli; F Lombardi; A Giovanninetti; F Mensi; S Villa
Journal:  Tumori       Date:  1988-10-31
  6 in total
  1 in total

1.  The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma.

Authors:  J Fisken; R C Leonard; M Stewart; G J Beattie; C Sturgeon; L Aspinall; J E Roulston
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.